+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Astellas Pharma, Inc. - logo

Astellas formed in 2005 through the merger of Yamanouchi and Fujisawa. The company employs over 400 people in Ireland across three locations. It has successfully launched innovative products and established itself as a category leader in the therapeutic areas of Transplantation and Urology. Astellas Pharma is one of the world’s top 20 pharmaceutical companies, employing 15,000 people globally. Its headquartered at the Citywest Business Campus in Dublin 24.

From
Gastrointestinal Collaboration and Licensing Deals 2016-2025 - Product Thumbnail Image

Gastrointestinal Collaboration and Licensing Deals 2016-2025

  • Report
  • April 2025
  • 200 Pages
  • Global
From
Mayus Kinase 3 (JAK3) Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Mayus Kinase 3 (JAK3) Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Protein Kinase C (PKC) Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Protein Kinase C (PKC) Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
IkappaB Kinase (IKK) Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

IkappaB Kinase (IKK) Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Diabetic Neuropathy Market Report and Forecast 2023-2031 - Product Thumbnail Image

Diabetic Neuropathy Market Report and Forecast 2023-2031

  • Report
  • May 2023
  • 160 Pages
  • Global
From
From
From
Chronic Kidney Disease - Epidemiology Forecast to 2032 - Product Thumbnail Image

Chronic Kidney Disease - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
From
From
Loading Indicator